[go: up one dir, main page]

US9888999B2 - Acellular dermal allografts and method of preparation - Google Patents

Acellular dermal allografts and method of preparation Download PDF

Info

Publication number
US9888999B2
US9888999B2 US13/389,937 US201013389937A US9888999B2 US 9888999 B2 US9888999 B2 US 9888999B2 US 201013389937 A US201013389937 A US 201013389937A US 9888999 B2 US9888999 B2 US 9888999B2
Authority
US
United States
Prior art keywords
allograft
irradiation
dermal
skin tissue
epidermis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US13/389,937
Other languages
English (en)
Other versions
US20130013068A1 (en
Inventor
James Forsell
Frank Fan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elutia Inc
Elutia Med LLC
Original Assignee
Aziyo Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US13/389,937 priority Critical patent/US9888999B2/en
Application filed by Aziyo Biologics Inc filed Critical Aziyo Biologics Inc
Publication of US20130013068A1 publication Critical patent/US20130013068A1/en
Assigned to AZIYO BIOLOGICS, INC. reassignment AZIYO BIOLOGICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TISSUE BANKS INTERNATIONAL, INC.
Assigned to TISSUE BANKS INTERNATIONAL reassignment TISSUE BANKS INTERNATIONAL ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FORSELL, JAMES, FAN, FRANK
Assigned to ALOSTAR BANK OF COMMERCE reassignment ALOSTAR BANK OF COMMERCE SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AZIYO BIOLOGICS, INC.
Assigned to MIDCAP FINANCIAL TRUST, AS AGENT reassignment MIDCAP FINANCIAL TRUST, AS AGENT SECURITY INTEREST (REVOLVING) Assignors: AZIYO BIOLOGICS, INC., AZIYO MED, LLC
Assigned to MIDCAP FINANCIAL TRUST, AS AGENT reassignment MIDCAP FINANCIAL TRUST, AS AGENT SEURITY INTEREST (TERM) Assignors: AZIYO BIOLOGICS, INC., AZIYO MED, LLC
Publication of US9888999B2 publication Critical patent/US9888999B2/en
Application granted granted Critical
Assigned to MIDCAP FINANCIAL TRUST, AS AGENT reassignment MIDCAP FINANCIAL TRUST, AS AGENT REAFFIRMATION & AMENDMENT TO SECURITY INTEREST (TERM) Assignors: AZIYO BIOLOGICS, INC., AZIYO MED, LLC
Assigned to MIDCAP FINANCIAL TRUST, AS AGENT reassignment MIDCAP FINANCIAL TRUST, AS AGENT REAFFIRMATION & AMENDMENT TO SECURITY INTEREST (REVOLVING) Assignors: AZIYO BIOLOGICS, INC., AZIYO MED, LLC
Assigned to SWK FUNDING LLC reassignment SWK FUNDING LLC SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AZIYO BIOLOGICS, INC., AZIYO MED, LLC
Assigned to MIDCAP FINANCIAL TRUST reassignment MIDCAP FINANCIAL TRUST RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: AZIYO BIOLOGICS, INC., AZIYO MED, LLC
Assigned to MIDCAP FUNDING IV TRUST reassignment MIDCAP FUNDING IV TRUST RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: AZIYO BIOLOGICS, INC., AZIYO MED, LLC
Assigned to ELUTIA INC. reassignment ELUTIA INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: AZIYO BIOLOGICS, INC.
Assigned to ELUTIA MED LLC reassignment ELUTIA MED LLC CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: AZIYO MED, LLC
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/10—Hair or skin implants
    • A61F2/105—Skin implants, e.g. artificial skin
    • A01N1/0294—
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/16—Physical preservation processes
    • A01N1/168—Physical preservation processes using electromagnetic fields or radiation; using acoustic waves or corpuscular radiation

Definitions

  • the present invention generally relates to the field of tissue processing and grafting; particularly to a method for preparing sterilized human acellular dermal (“ACD”) allografts that may be stored for prolonged periods before use.
  • ACD sterilized human acellular dermal
  • Skin has the same overall structure in all vertebrate organisms. It is made of an exterior layer called the epidermis, a basement membrane layer, a dermis layer, and a subcutaneous layer of adipose tissue and protein fibers. Of course, skin tissue removed from any vertebrate cadaver may contain additional attached soft tissue.
  • the epidermis is a thin, elastic, waterproof outer layer of the skin. It contains a majority of the cells found in the skin. The majority of the cells in the epidermis are keratinocytes. The tough, fibrous-like protein produced by these cells is known as keratin. Keratinocytes are self-replacing cells; the keratinocytes in the lower (interior) portion of the epidermis divide and push upward over time to replace older keratinocytes, which eventually reach the skin's outer surface and are sloughed off. Also, present in the epidermis is the pigment producing melanocyte. Another cell type, the Merkel cell, is also present in the epidermis.
  • the basement membrane is a thin but complex layer. Its molecular structure is of such a nature as to provide a mechanism to hold the skin together. When preparing allografts, artisans skilled in the art deem it is critical to provide dermal skin with an essentially intact basement membrane. See U.S. Pat. No. 5,336,616.
  • the dermis is comprised primarily of collagen, which gives the skin structure and strength. Dermis also contains elastin, which is responsible for the skin's flexibility. The collagen and elastin are produced by fibroblast cells residing in the dermis. The upper part of the dermis contains a papillary layer, having molecules that help bind the dermis to the epidermis. Blood vessels grow into the dermis, spreading into the upper part of the dermis.
  • the skin is a critical organ. Deep injuries to the skin, if not treated promptly, can lead to loss of life.
  • the skin provides protection against foreign infectious agents, prevents fluid loss, and helps regulate body temperature. Treatment of injuries to the skin, in particular deep injuries, often requires the use of skin allografts. When skin allografts are used in burn or other topical (skin replacing skin) applications, immune cells from the patient, fibroblast cell precursors, and other cell types press against the epidermis and slough off the allograft, as healing occurs.
  • an autograft is provided, if such skin tissue, in sufficient quantity and quality, is available by surgical removal from another part of the same person's body or can be timely generated (grown/expanded-cultured) from a patient's own skin.
  • This approach (the use of skin obtained surgically from the same patient) would render moot the issue of immune rejection of the allograft.
  • skin from a cadaver, or even skin from some animals (xenograft) is used instead of an autograft.
  • Fresh skin allografts have many limitations. One limitation is their short storage life, making their availability an issue. Typically, complications can result from issues of immunogenicity and sterility with these allografts. However, out of necessity, such allografts are used because the temporary benefit of covering the wound while the patients repair and defenses build up outweighs any complications arising from sterility and of the eventual immune rejection of the allografted skin.
  • Tissue banks have minimized the disease transmission risk of skin allografts with careful donor screening (medical history) practices, serological testing, microbiological testing, applying certain antibiotics, and with the utilization of sterile technique throughout the tissue handling, processing, storage, and distribution stages.
  • donor screening medical history
  • serological testing epidermis and dermal tissue
  • microbiological testing epidermis and dermal tissue
  • the entire surgical process is aseptic and the recovered allograft is stored in media containing antibiotic(s).
  • AATB American Association of Tissue Banks
  • the AATB Standards reflect best practices in every aspect of tissue bank work and include bank organization, collection, transport, processing and distribution of tissue. See Standards for Tissue Banking, 12th edition, Implementation Date Jun. 1, 2008, co-edited by K. Pearson, N. Dock, and S. Brubaker, Library of Congress Card No. 84-7269.
  • Skin allografts comprising epidermis are well suited for skin replacement applications but are not well suited for procedures including periodontal procedures, hernia repair, or wrapping around metal plates and pins.
  • the dermal portion of the skin which is the topic of the present invention, is better suited to these applications.
  • Dermal allografts retaining cellular content are also not well suited for some procedures, and increase likelihood of immune rejection and infection.
  • a sterile, pliable acellular dermal allograft which is easy to use in surgical settings, has reduced immunogenicity, can be more easily repopulated by the patient's own cells and can be stored safely for a longer time, would be advantageous.
  • the product would be a terminally sterilized acellular dermal allograft, which would eliminate the potential for infection from the donated skin to the recipient.
  • a terminally sterilized acellular product is easier for doctors to use because it is sterilized and conforms to standard operating room procedures.
  • the invention provides a method of preparing an irradiation sterilized acellular dermal allograft that can be stored for periods of at least about 3 years before use in grafting procedures.
  • the method comprises obtaining skin tissue; processing the skin by serial exposure, first to a first cell removal solution, followed by exposure to an epidermis removal solution; removing the epidermis to produce a dermal allograft; optionally again exposing the allograft to a cell removal solution; exposing the allograft to a gamma ( ⁇ ) irradiation protection solution; placing the allograft in a storage container; preparing the allograft for irradiation by performing at least one step from among: drying the allograft by freeze drying (lyophilization), freezing the allograft or placing the allograft in saline; and exposing the allograft to irradiation; whereby the skin tissue can then be stored until use for periods of up to at least about 3 years.
  • the skin may be stored in glycerol at ⁇ 20° C. to 10° C. for up to about 5 years.
  • the graft Prior to storage in glycerol, the graft is treated by exposure to at least two increasing concentration of glycerol, the lowest concentration being about 25% (v:v) and the highest about 100% (v:v).
  • the exposure to increasing concentration of glycerol comprises exposure to 50%, 75% and 100% glycerol (v:v).
  • the cell removal solution comprises at least two detergents.
  • One of the at least two detergents is deoxycholate at a concentration of about between 1% to 10% (v:v).
  • the epidermis removal solution comprises about between 0.2% and 2% (v:v) detergent.
  • the ⁇ irradiation protection solution comprises at least two sugars and one sugar is trehalose.
  • the container is a bag made of polyethylene and spunbond high density polyethylene fiber (Poly-Tyvek®).
  • the skin tissue is placed in a stabilization media prior to exposure to a first cell removal solution.
  • the stabilization media is a cell growth media which contains an antibiotic.
  • the step of preparing the allograft for irradiation comprises placing the allograft in saline inside a container and in which case, the step of exposure to the ⁇ irradiation protection solution is optional.
  • the allograft after the step of preparing the allograft for irradiation, may be stored for up to about one year before irradiation.
  • the radiation is ⁇ -radiation.
  • the ⁇ -radiation is from Cobalt 60 or Cesium 137 .
  • the irradiation is from Cobalt 60 .
  • the irradiation delivers an absorbed radiation dose of 5-35 kGy.
  • the absorbed radiation dose is about 10-23 kGy, and, more preferably, the absorbed radiation dose is about 17-23 kGy.
  • the invention provides a sterile acellular dermal allograft whose characteristics comprise:
  • the allograft was made sterile by having absorbed between about 5-35 kGy ⁇ -irradiation;
  • the allograft has an intact matrix and is pliable
  • the allograft has a reduced cellular content, reduced bioburden and reduced immunogenicity properties
  • the allograft has ductility, re-cellularization, adhesion and revascularization properties significantly similar to a non-irradiated dermal allograft;
  • the allograft has a shelf life of up to at least about 3 years.
  • the dermal allograft may be used in soft tissue repair.
  • the dermal acellular allograft has absorbed 10-23 kGy of irradiation, preferably 17-23 kGy of irradiation.
  • irradiation is from Cobalt 60 or Cesium 137 .
  • FIG. 1 is a flow chart illustrating primary processing steps for a terminally sterilized, full thickness, freeze-dried acellular dermal allograft, according to one embodiment of the present invention.
  • the current invention provides a method for preparing an acellular dermal (ACD) allograft and the allograft produced thereby, where the allograft is sterile or has a greatly reduced bio-burden, contains no viable cells, and has a long shelf life, i.e. can be easily used by surgeons in soft tissue replacement or repair for a period of time of up to at least about 3 years.
  • the ACD remains pliable.
  • the process of preparation includes exposure of the allograft to radiation, preferably ⁇ -radiation, more preferably Cobalt 60 or Cesium 137 radiation, although other sources and types of energy such as x-ray and electron beam may be used.
  • the preferred timing of the irradiation step is towards the end of the overall process, after removal of cells and the epidermis from the allograft and after its packaging, i.e. the allograft preferably is “terminally sterilized.”
  • the terminally sterilized allograft in its package remains sterile until opened and exposed to the environment at the time of the surgical procedure. This minimizes the chance of the allograft becoming contaminated before used in a patient.
  • sterilization by irradiation might occur earlier in the process of preparing the dermal allograft.
  • the terminally sterilized allograft of the invention is prepared from human skin and, more preferably, it is from a recently deceased human (cadaver), for use in allografting.
  • cadaver a recently deceased human
  • this invention can be applied also to autografting and xenografting.
  • FIG. 1 illustrates a flow chart of the steps of the method of the present invention, according to one embodiment.
  • the order of the steps listed in FIG. 1 is illustrative of only one embodiment of the invention. Some of the steps listed in FIG. 1 are optional, as discussed herein elsewhere.
  • FIG. 1 relates, in particular, to incorporation of a freeze drying alternative step and the preparation of full thickness dermal allograft.
  • the method of recovery/removal of the skin from the cadaver, the requirements for a medically acceptable skin-tissue source, and the transport for use in transplantation are, in many respects, similar to the methods and the standards of the industry.
  • the methods and typical standards are in accordance with the American Association of Tissue Banks' Current STANDARDS FOR TISSUE BANKING, supra.
  • the method of recovering and qualifying tissue includes recovery from, preferably, a recently deceased cadaver (i.e.
  • obtaining extensive information about the donor to include the medical condition, a medical and social history, tissue donor consent, serology reports, physical assessment by the skin surgical recovery team, hemodilution assessment, and an autopsy report.
  • the skin obtained for the invention is recovered from any suitably sized area of the body, but preferably, it is from the back or the posterior and anterior parts of the legs. It can be recovered using a dermatome or by using other surgical instruments.
  • the dermatome process and equipment is similar in most ways with the standardized use of this medical instrument by burn surgeons.
  • the dermatome is likelier to produce an initial graft having a more even thickness and comprising less adipose tissue.
  • “Extra-Thick” (sometimes referred to as “Xtra thick”) is recovered by well-established surgical procedures using standard surgical instruments other than dermatome. The thickness of Xtra thick will range from about 1.50 mm to about 3.00 mm, sometimes up to about 4.0 mm.
  • Full thickness is recoverable by dermatome or possibly surgical instruments.
  • the range of thickness for an original full-thickness graft is from about 0.20 mm to about 2.00 mm.
  • Extra-Thick For an allograft destined for use in breast reconstruction or abdominal repair—which requires a thicker and stronger tissue, often the method of choice is Extra-Thick. These terms are well understood by artisans of ordinary skill in the art. An artisan skilled in the art will know which method to use to obtain, Extra-Thick, full thickness or dermatome prepared tissue, and which tissue is more appropriate, depending on the source of the skin and its intended use.
  • a storage/transport media also referred to as “stabilization” media.
  • a number of media are suitable, such as various cell culture media, often including at least one antibiotic.
  • a preferred media is Roswell Park Memorial Institute 1640 (RPMI 1640), including gentamycin as an antibiotic.
  • RPMI 1640 is a well-known cell culture and tissue storage/transport media. Its composition is known. Artisans skilled in the art often use the RPMI media supplemented with components, such as antibiotic(s) or growth factors, or essential amino acids, or other common supplements for a variety of purposes.
  • RPMI 1640 is available commercially from, inter alia, Sigma-Aldrich Corporation, St. Louis, Mo. The media composition was initially published by Moore et al., JAMA 199:8, pgs. 519-524 (1967).
  • Samples of the media after exposure to the recovered tissue undergoes microbiology testing to determine presence of contaminants. Preliminary results are available within about three days, final results take up to about 12 days.
  • required serology tests on the donor of the dermis/skin include HIV, hepatitis, T-lymphotropic virus and syphilis. The test results are reviewed before final processing of the tissue and unsuitable tissue is discarded at whatever processing step it has reached when the test results are reviewed.
  • the skin should not be kept in the media (even with periodical changes of the media) for more than 14 days after retrieval.
  • the recovered skin in media is kept at a temperature of between 1° C. to 10° C. (see Standard for Tissue Banking 12th Edition, American Association of Tissue Banks. Section E4.110 Refrigerated Tissue). If the skin is shipped to a different facility (a processing facility), the temperature range required for the duration of the transportation are the same as for storage.
  • the skin is processed to obtain the desired thickness, to remove adipose and other soft tissue, and to trim away uneven edges and any defective areas.
  • the desired thicknesses of the processed skin allograft ranges from about 0.2 to about 4.0 mm. The desired thickness is determined by consideration of the surgeon's needs and intended use. The thickness range might change over time as required by the standard of practice in the surgical applications.
  • the skin is, optionally, subjected to glycerol treatment to remove water from the skin.
  • the process requires treatment with increasing concentrations of glycerol, starting with a concentration of at least about 25%, ending with exposure to up to about 100% glycerol, each at a temperature of from about 10° C. to about 10° C., preferably at about 4° C.
  • the skin is placed in at least about 1 to 4 volumes of the glycerol solution (to one volume of skin), for from about 1 hour to about 24 hours. If possible, the solution is agitated during at least a portion of this time. The agitation is at between approximately 50 rpm and 200 rpm.
  • the skin is exposed to three glycerol concentrations, about 50%, 70%, and 100% glycerol, each for about 1-24 hours.
  • the skin product can be then stored in 100% glycerol at a temperature of from about ⁇ 20° C. to about 10° C., for up to about five years.
  • the above glycerol protocol is optional for the performance of the present invention. Typically, it is used when the fresh skin is not processed before the 14 days expiration date for fresh skin tissue.
  • the glycerol Prior to processing to remove the epidermis and cells, the glycerol is removed by washing the skin with a normal saline solution or equivalent. Preferably, there are at least two washes, each of about 1 to 5 volumes of saline solution or equivalent to the volume of the skin, with agitation at 50 1200 rpm, each wash for between 15 and 120 minutes. Of course, if the above glycerol processing step is skipped, the saline wash step may be skipped as well.
  • the process to remove cells and the epidermis includes separate washes with a Cell Removal Solution (“CRsol”) and an Epidermis Removal Solution (“ERsol”). Multiple scenarios were tested, including the order and number of washes. Various options produce more or less acceptable results. However, preferably, there is a wash in CRsol first, a wash in ERsol next, normally the epidermis is then removed, followed by another CRsol wash. It is possible to introduce additional washes and changes of the wash solutions to fresh solutions. However, if the ERsol wash occurs first, the epidermis removal is difficult and inefficient. All the washes are preferably performed at room temperature and the volume of skin to solution is at least 1:1 or more, with 1:3 being preferred.
  • the preferred CRsol and ERsol include detergents (two or more detergents in the CRsol, preferably deoxycholate (3,12 a-dihydroxy-5(3-cholan-24-oic acid) and either Triton® X-100, octoxynol or polysorbate).
  • detergents two or more detergents in the CRsol, preferably deoxycholate (3,12 a-dihydroxy-5(3-cholan-24-oic acid) and either Triton® X-100, octoxynol or polysorbate.
  • no enzymes are added to either the ERsol or CRsol. Enzymes might compromise the matrix and, if enzymes are present, the cells and epidermis removal is typically not optimal.
  • the ERsol contains at least about 0.5M NaCL or an equivalent salt.
  • the washes in CRsol are for 1-48 hours, each.
  • the CRsol composition can be the same (but does not have to be identical) for the two washes using CRsol.
  • the wash in ERsol is for 1 to 72 hrs, or longer.
  • the Extra-Thick or full-thickness skin products will usually require a longer ERsol wash and CRsol wash, each for up to about 72 hrs. It will also involve at least one change of the ERsol, after an overnight wash of about 1-24 hours.
  • the preferred CRsol is a phosphate buffered saline solution containing Ethylenediaminetetraacetic Acid (EDTA) or another chelating agent and large concentrations of detergent(s).
  • EDTA Ethylenediaminetetraacetic Acid
  • a preferred detergent is deoxycholate. More preferably, the solution contains about 1.0 to 10% deoxycholate and yet more preferably, about 5% deoxycholate.
  • the CRsol contains two detergents and, preferably, one of the two detergents is deoxycholate at the above-indicated concentrations.
  • the second detergent may be, for example, polyethylene glycol p-tert-octylphenyl ether (Triton® X-100), sodium dodecyl sulfate or polysorbate.
  • a preferred second detergent is Triton® X-100 at about 0.5-5.0%, preferably at about 0.75%.
  • the chelating agent is preferably EDTA at a concentration of 0.005 to 0.05 M, preferably 0.01 M.
  • the solutions are typically made up to a pH of about 7.0-10.0, preferably about 8.5. Phosphate buffer solutions are well known, can easily be prepared and are available also commercially.
  • the ERsol is a water-based solution containing electrolytes, EDTA or another chelating agent and limited concentrations of detergent(s).
  • the ERsol might comprise, Triton® X-100 detergent at a concentration of less than about 0.2%, preferably at about 0.05%, and an electrolyte such as sodium chloride at a concentration of 0.5 to 2.0 M, preferably about 1.2 M.
  • the chelating agent is preferably EDTA at a concentration of 0.05 to 0.5 M, preferably about 0.1 M.
  • the solutions are typically made up to a pH of about 6.5-10.0, preferably about 8.0.
  • the ERsol might include somewhat larger amounts of detergent(s) than the ERsol for full thickness skin processing and might comprise also a pH buffer.
  • the ERsol might comprise Triton® X-100 at a concentration of less than about 2.0%, preferably at a concentration of less than about 1%, and more preferably at about 0.7%, and deoxycholate at a concentration of 1.0-4.0%, preferably about 2%.
  • the electrolyte is preferably sodium chloride at a concentration of 0.5 to 2.0 M, preferably about 1.0 M.
  • the chelating agent is preferably EDTA at a concentration of 0.05 to 1.0 M, preferably 0.15 M.
  • the pH buffer is preferably phosphate at a concentration of about 0.05-0.5, typically about 0.15 M.
  • the solutions are typically made up to a pH of about 6.5-10.0, preferably about 8.0.
  • the skin is practically free of any cellular content.
  • the epidermis is removed easily by dissecting apart the two layers.
  • the last wash, after the epidermis removal is another at least one CRsol wash.
  • the skin is next exposed to a wash in a Gamma Irradiation Protection Solution (“GIPS”).
  • GIPS contains at least two sugars.
  • One preferred sugar is trehalose.
  • Other preferred sugars might be maltose, dextrose or fructose.
  • the preferred GIPS is about 10% to 50% of trehalose and one or more other sugars, such as 10% to 50% maltodextrin, in phosphate saline buffer.
  • the wash in the GIPS is at room temperature for 0.5 to 24 hrs, in at least 1:1 to 1:5 (v:v) (skin:solution), with agitation at a speed of at least 50 rpm to 200 rpm.
  • the skin is placed on a cutting board, inspected and is cut into pieces of the desired size and shape.
  • the produced allograft pieces might be small, about 1 ⁇ 1 cm for certain procedures, e.g. gingivitis treatment (cover the root of teeth), or larger, e.g. about 20 ⁇ 20 cm for larger burns or wounds.
  • a variety of instruments may be used to cut the dermis, including a scalpel or a laser-cutting instrument. Of course, the surgeon will likely further shape and trim the graft as needed, before implantation.
  • the allograft pieces are next placed onto a meshed material.
  • Use of mashed backing material is known in the art.
  • the material is typically bio-compatible. It is placed in a manner to identify the basal membrane side of the allograft.
  • the mashed material improves the ease of handling of the allograft, the ease of use of the allograft by the surgeon, and identifies the side of the allograft where the basement membrane layer is located.
  • the dermis is then placed into a container.
  • the container may be of a suitable material including glass, plastic, or, preferably, Poly-Tyvek® or similar pouches, having at least one porous side.
  • Multiple allograft pieces from the same donor may be stored in one container/pouch.
  • each allograft piece is stored in a separate pouch.
  • the pouches may be stored at a temperature from about 1° C. to about 100 C prior to the next step. Typically, a measurement of the resulting tissue thickness is undertaken.
  • the tissue is frozen to at least about ⁇ 20° C. or colder, preferably ⁇ 40° C. or colder, up to about ⁇ 80° C.
  • the tissue is placed in a container in a normal saline media and kept at room (ambient) temperature before the sterilization/irradiation step.
  • the previous step of a wash in GIPS solution is optional.
  • the tissue, prior to sterilization is subject to a lyophilization step, to remove water content from the allograft.
  • the lyophilization process is time and temperature sensitive.
  • the lyophilization is carried out by standard procedures known in the art. See, for example, D. Michael Strong and Allen P. MacKenzie, Freeze-drying of Tissues (Chapter 5 and references included therein) in Musculoskeletal Tissue Banking, edited by William W. Tomford, Raven Press (1993).
  • the lyophilization approach includes a step of testing a few sacrificed samples for their moisture content as a quality check for the lyophilization process. AATB requirements are that the residual moisture is between 0 and 6%.
  • the dermal allograft pieces may be stored at 1° C. to 10° C. after processing and before sterilization, for up to about 1 year. If frozen, the tissue could be stored at about ⁇ 40° C. or colder preferred for up to at least one year before sterilization.
  • the allograft pieces in a container e.g. the Poly-Tyvek® bags, glass bottles, etc.
  • a container e.g. the Poly-Tyvek® bags, glass bottles, etc.
  • the sterilization is accomplished by irradiation. It is desired that the irradiation have a short wavelength to enhance penetration of the radiation into and throughout the dermal tissue.
  • the radiation used to achieve sterilization of the dermis is ⁇ -radiation.
  • the sterilization is enhanced because the ⁇ -radiation can provide complete penetration of the container, packaging and dermal tissue and provide a more predictable bacterial, viral, or fungal inactivation.
  • Microorganisms including both enveloped and non-enveloped RNA and DNA viruses, are susceptible to inactivation by ⁇ -radiation. Additionally, any remaining cells, if any, will be inactivated by the irradiation.
  • the sterilization is by Cesium 137 or Cobalt 60 ⁇ -radiation.
  • the sterilization is by Cobalt 60 radiation. It will be recognized by an artisan skilled in the art that Cobalt 60 produces a particularly short wave-length energy within the gamma ray range, and the short wave energy is highly penetrative.
  • the irradiation is carried out in a temperature-controlled environment, at between ⁇ 30° C. (typically, in dry ice) to room ambient temperature, although it is preferred to irradiate at below 10° C.
  • the preferred temperature at which irradiation is performed is dependent on the state of the sample.
  • a sample which is frozen is irradiated while maintaining the temperature such that the sample remains frozen.
  • a sample which has been previously lyophilized or stored in saline is irradiated preferably at a cool temperature, preferably below 10° C. and more preferably at about 0-4° C.
  • the processed dermal allograft pieces are placed in containers or vials suitable for the irradiation. These containers/vials can be constructed of various materials, including plastic and glass.
  • the process is optimized and monitored for reproducible dose delivery of the radiation.
  • the sterilization occurs in a temperature-controlled environment at from about ⁇ 20° C. to room temperature.
  • the effective dose of absorbed irradiation is from about 5-35 kiloGrays (“kGy”).
  • the absorbed dosage is from 10-30 kGy, and more preferably from 10-23 kGy. It will be recognized by an artisan skilled in the art that 5-35 kGy are very high levels of absorbed radiation.
  • the resultant allograft dermal tissue is now virtually acellular, pliable, and has a somewhat reduced basement membrane volume.
  • the irradiated allograft has a bioburden load reduced by at least a factor of 10 ⁇ 4 (4 logs).
  • the bioburden is reduced to at least about the Sterility Assurance Level (SAL) of 10 ⁇ 6 .
  • SAL Sterility Assurance Level
  • the irradiation techniques, procedures, and methodologies employed by the current invention comply with standards and requirements known to those skilled in the art.
  • the effectiveness and efficiency of the irradiation of the grafts depends on several factors, such as the duration of time during which a dosage of irradiation is applied, the type of irradiation, the distance the source of the irradiation is from the sample, any shielding effects, and other considerations as can be contemplated by those of ordinary skill in the art.
  • the radiation may have to penetrate various other surfaces and materials, such as through a box containing samples of dermal allografts within vials that may contain a fluid or other packaging materials/systems.
  • the factors that should be accountable include, for example, the size and volume of vials, and their density and configuration.
  • the radiation must uniformly, effectively and efficiently penetrate the cardboard of the box and the allograft container material (e.g. a bag, or a vial, etc., typically a vial, made of, for example, glass or plastic) and be able to deliver effectively the targeted absorbed dose uniformly in a tight range to the dermal allografts to provide the degree of bioburden reduction of the current invention.
  • the irradiation process is often outsourced to firms with sophisticated irradiation machinery, such as NordionTM Inc., Ottawa, Ontario, Canada or STERISTM Corporation, Mentor, Ohio.
  • Various methods known in the art are employed to determine the quality of the product, its microbial load, transparency, and pliability. Such quality monitoring steps may involve the sacrifice of some processed grafts for specific testing purposes.
  • the irradiation is delivered for a duration of from about 30 to about 300 minutes.
  • the duration of the irradiation dosage can be a factor of the half-life of the -y-irradiation source.
  • the duration of the dosage may be influenced by the various factors described above or other factors known to those knowledgeable in the art.
  • the irradiation dose needed for sterilization is validated on a regular basis, typically at least once per calendar quarter by a recognized scheme for sterility such as VD max 15—described in ANSI/AAMI/ISO 11137-1:2006: Sterilization of Health Care Products. Additionally, exposure is monitored in each run by dosage mapping to insure proper dosing.
  • the container and/or storage device housing the media solution, if used, and the allograft, once irradiated, are preferably not exposed to the environment, which could lead to a loss of sterility.
  • the allograft once irradiated, the allograft preferably will not be exposed to further processing or changing of media.
  • sterilization may take place earlier in the chain of events, followed by aseptic handling of the tissue.
  • the dermal graft material is preferably stored at a temperature from 1° C. to 10° C. and it may be stored at ambient temperature.
  • the allograft must remain in a frozen state until it is prepared for surgical use.
  • Shelf life is a function of packaging and the intrinsic stability of the content, itself.
  • a sterilized graft in a robust, closed container described herein remains sterile and useful for at least up to about 3 years, or longer. Testing of tissue pliability, cell content, medical records review, process quality steps as well as bioburden testing are performed prior to and after sterilization procedures of the dermal allografts in the current invention.
  • the reduction in allergenic cells and microorganisms levels in the processed tissue provides a safer allograft, much less likely to trigger an immune reaction from the patient and less likely to produce infections. Microbial contaminations are virtually eliminated based on the incoming bioburden and the sterilization to a SAL of 10 ⁇ 6 .
  • the sterilized acellular dermal allograft was tested and shown to compare well with other dermal grafts in respect to physical characteristics, such as pliability, the ability to undergo cell repopulation, and effectiveness in repairing wounds or other soft tissue repairs.
  • the inventor performed animal testing and concluded that the immune response to the allograft is limited and not a clinically important factor in the utility of the tissue.
  • human ACD was implanted in rabbit (an abdominal wall repair model) to compare adhesion rate, recellularization and revascularization between irradiated and non-irradiated ACD.
  • rabbit an abdominal wall repair model
  • These animal model studies showed equivalent repair between the irradiated dermis and non-irradiated dermis, as demonstrated by comparing re-cellularization, revascularization and adhesion.
  • the irradiated allograft showed the same limited adhesion property on the basement membrane surface as the non-irradiated allograft.
  • the irradiated allografts compared well with the results obtained with non-irradiated dermis.
  • the current invention provides a sterile dermal allograft.
  • the dermal allograft may be used in any soft tissue repair and reconstruction, such as but not limited to breast reconstructive surgery; abdominal wall repair; orthopedic surgery; dental surgery; plastic and reconstructive surgery; dental procedures; burn surgery; etc.
  • the allograft is a dermal allograft sterilized by ionizing radiation in a controlled temperature environment of from about ⁇ 20° C. to 50° C. with an effective dose of absorbed irradiation from about 10-30 kGy, to achieve a preferred SAL of 10 ⁇ 6 .
  • the allografts of the current invention have reduced enzymatic and metabolic activity, and reduced antigenic properties.
  • the irradiated dermal allograft of the invention is pliable and is capable of effective re-population by the patient's own cells, in situ or, for that matter, in-vitro.
  • the matrix is not only sterile and cell free, it is architecturally intact.
  • the sterilized matrix can be used as a scaffold for cell culturing procedures/techniques.
  • the properties of the allograft of the invention have been demonstrated repeatedly by histopathology and electron microscopy studies.
  • the terminally sterilized acellular dermal allograft has a reduced count of viable human cells.
  • the sterilized graft has an essentially intact collagen structure.
  • the intact collagen structure plays a large role in the tissue's ability to maintain its effectiveness for grafting procedures.
  • Albeit the basal membrane content is not a particular concern of the procedure, it has been noted that the basal membrane is present, albeit slightly reduced in volume.
  • the irradiation process causes a limited amount of cross-linking of the structural elements of the graft, resulting in a slightly more sturdy structure.
  • the allograft requirements differ, based on surgical application and surgeon's preferences.
  • the invention allows also for the modification of the toughness/ductility (ability to stretch) of the tissue by irradiation, within the irradiation ranges specified for the invention.
  • the inventor has tested ductility over the preferred dose range of 10-23 kGy.
  • the ductility of dermis dropped about 11.6% over this range, which was statistically significant. Using the entire range of 10-30 KGy would give the ability to further control ductility.
  • the dermal graft ductility was conducted using a standard uniaxial tension test.
  • Fifty-two dermal graft tensile bars were tested.
  • the series constituted three donors (with three matched sets) of non-irradiated and ⁇ -irradiated tensile testing specimens.
  • the absorbed radiation was at 17 to 23 kGy for freeze-dried derma, in each test.
  • the non-irradiated samples failed with strain at maximum load of 58.6%, the irradiated tissue failed with strain at 47%. This decrease in ductility was barely significant at a 95% confidence level (p-value ⁇ 0.05).
  • the allograft is typically stored at a temperature from 1° C. to 10° C. Moreover, there is no detrimental effect on the allograft if storage is at any temperature, from about ⁇ 80° C. (colder if different packaging is used) to about 30° C. (Exception to this range is the frozen option, previously noted above).
  • the long storage of the terminally sterilized acellular dermal graft is a significant advantage whereby the graft can be stored for various periods and maintain its effectiveness for use.
  • the graft of the current invention can be stored after sterilization for up to about 3 years or more, while maintaining the sterility, pliability, ductility and reduced immunogenicity.
  • the processing may occur at the same facility where tissue is recovered; bio burden checks can be initially taken at time of tissue recovery and/or upon arrival at the processing center; or irradiation may take place before removal of the epidermis or at other time points, for example after the processing and thus being a “terminal” step in the method of preparation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Transplantation (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Vascular Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Materials For Medical Uses (AREA)
  • Physics & Mathematics (AREA)
  • Electromagnetism (AREA)
US13/389,937 2009-08-11 2010-01-04 Acellular dermal allografts and method of preparation Active 2033-07-10 US9888999B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/389,937 US9888999B2 (en) 2009-08-11 2010-01-04 Acellular dermal allografts and method of preparation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23309809P 2009-08-11 2009-08-11
US13/389,937 US9888999B2 (en) 2009-08-11 2010-01-04 Acellular dermal allografts and method of preparation
PCT/US2010/000003 WO2011019361A1 (fr) 2009-08-11 2010-01-04 Allogreffes dermiques acellulaires et procédé de préparation

Publications (2)

Publication Number Publication Date
US20130013068A1 US20130013068A1 (en) 2013-01-10
US9888999B2 true US9888999B2 (en) 2018-02-13

Family

ID=43586344

Family Applications (1)

Application Number Title Priority Date Filing Date
US13/389,937 Active 2033-07-10 US9888999B2 (en) 2009-08-11 2010-01-04 Acellular dermal allografts and method of preparation

Country Status (4)

Country Link
US (1) US9888999B2 (fr)
EP (1) EP2464221A4 (fr)
CA (1) CA2771032A1 (fr)
WO (1) WO2011019361A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD856517S1 (en) 2016-06-03 2019-08-13 Musculoskeletal Transplant Foundation Asymmetric tissue graft
US10702260B2 (en) 2016-02-01 2020-07-07 Medos International Sàrl Soft tissue fixation repair methods using tissue augmentation scaffolds
USD895812S1 (en) 2018-09-07 2020-09-08 Musculoskeletal Transplant Foundation Soft tissue repair graft
US10813743B2 (en) 2018-09-07 2020-10-27 Musculoskeletal Transplant Foundation Soft tissue repair grafts and processes for preparing and using same
US10945831B2 (en) 2016-06-03 2021-03-16 Musculoskeletal Transplant Foundation Asymmetric tissue graft
US11484401B2 (en) 2016-02-01 2022-11-01 Medos International Sarl Tissue augmentation scaffolds for use in soft tissue fixation repair

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9192695B2 (en) 2008-11-20 2015-11-24 Allosource Allografts combined with tissue derived stem cells for bone healing
US10207025B2 (en) * 2011-04-28 2019-02-19 Lifecell Corporation Method for enzymatic treatment of tissue products
AU2012249538B2 (en) 2011-04-28 2016-01-28 Lifecell Corporation Method for enzymatic treatment of tissue products
US9238793B2 (en) 2011-04-28 2016-01-19 Lifecell Corporation Method for enzymatic treatment of tissue products
WO2013049373A2 (fr) * 2011-09-27 2013-04-04 Spillman Deborah Marie Allogreffes de feuilles d'os cortical irradié et procédé de formation d'une allogreffe de feuilles d'os cortical irradié
WO2013147299A1 (fr) 2012-03-31 2013-10-03 学校法人早稲田大学 Tissu biologique et son procédé de traitement
EP3659633A1 (fr) 2013-02-06 2020-06-03 LifeCell Corporation Procédés pour modification localisée de produits tissulaires
EP2964154A4 (fr) 2013-03-07 2016-08-17 Allosource Systèmes et procédés d'allogreffe osseuse à teneur en calcium constante
AU2014244272B2 (en) 2013-03-14 2016-10-20 Musculoskeletal Transplant Foundation Soft tissue repair allografts and methods for preparing same
CN103272271B (zh) * 2013-05-22 2014-11-05 烟台正海生物技术有限公司 用于治疗疝气的外科补片及其制备方法
CN104174068B (zh) * 2013-05-22 2016-02-17 烟台正海生物科技股份有限公司 一种生物型软骨修复材料及其制备方法
CN104174069B (zh) * 2013-05-22 2016-06-29 烟台正海生物科技股份有限公司 一种致密骨基质及其制备方法
CN104174066B (zh) * 2013-05-22 2016-02-17 烟台正海生物科技股份有限公司 一种天然生物骨材料及其制备方法
CN103272272B (zh) * 2013-05-22 2014-11-19 烟台正海生物技术有限公司 一种天然具孔皮肤补片及其制备方法
CN103272270B (zh) * 2013-05-22 2014-11-19 烟台正海生物技术有限公司 一种管状外科补片及其制备方法
CN103239760B (zh) * 2013-05-22 2014-11-05 烟台正海生物技术有限公司 防粘连外科补片及其制备方法
CA2919374C (fr) 2013-07-30 2019-12-03 Musculoskeletal Transplant Foundation Matrices derivees de tissu mou acellulaire et leurs procedes de preparation
WO2015066668A1 (fr) 2013-11-04 2015-05-07 Lifecell Corporation Procédé d'élimination d'alpha-galactose
US10709811B2 (en) * 2014-10-31 2020-07-14 The Administrators Of The Tulane Educational Fund Surgical grafts for replacing the nipple and areola or damaged epidermis
US10912864B2 (en) 2015-07-24 2021-02-09 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
US10729812B2 (en) 2015-12-10 2020-08-04 Novothelium, Llc Human nipple areolar complex extracellular matrix scaffold and methods relating thereto
EP3463500A1 (fr) 2016-06-03 2019-04-10 LifeCell Corporation Procédés de modification localisée de produits tissulaires
EP3558405A1 (fr) 2016-12-22 2019-10-30 LifeCell Corporation Dispositifs et procédés de cryobroyage de tissu
WO2020014248A1 (fr) * 2018-07-09 2020-01-16 Arthrosurface, Inc. Moules pour former des implants d'allogreffe dermique et implants d'allogreffe dermique formés à partir de ceux-ci
US20210085443A1 (en) * 2019-09-25 2021-03-25 Allosource Pre-shaped allograft implant for reconstructive surgical use and methods of manufacture and use
EP4346933A1 (fr) * 2021-05-28 2024-04-10 Stratatech Corporation Produits kératinocytaires cultivés allogéniques
WO2023285859A1 (fr) * 2021-07-14 2023-01-19 Fonseca Canteros Marcelo Andres Procédé d'acquisition et d'utilisation de tissu pour allogreffes
CN114767938B (zh) * 2022-04-26 2023-11-24 北京桀亚莱福生物技术有限责任公司 用于盆腔脏器脱垂治疗的脱细胞异体真皮悬吊补片

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5336616A (en) 1990-09-12 1994-08-09 Lifecell Corporation Method for processing and preserving collagen-based tissues for transplantation
US5613982A (en) 1994-03-14 1997-03-25 Cryolife, Inc. Method of preparing transplant tissue to reduce immunogenicity upon implantation
US5613892A (en) 1995-03-31 1997-03-25 Barton; Leslie W. Inflatable plush toy
US20030185702A1 (en) * 2002-02-01 2003-10-02 Wilson Burgess Methods for sterilizing tissue
US20040219133A1 (en) * 2003-03-21 2004-11-04 Lyles Mark B. Keratinocyte-fibrocyte concomitant grafting for wound healing
US20050221484A1 (en) 2002-03-06 2005-10-06 University Of Cincinnati Apparatus for preparing a biocompatible matrix
US20060073592A1 (en) * 2004-10-06 2006-04-06 Wendell Sun Methods of storing tissue matrices
US20060275377A1 (en) * 2005-03-16 2006-12-07 Musculoskeletal Transplan Foundation Soft tissue processing
US20070269791A1 (en) 2003-12-25 2007-11-22 Yoshisiro Takami Method of Preparing Isolated Cell-Free Skin, Cell-Free Dermal Matrix, Method of Producing the Same and Composite Cultured Skin with The Use of the Cell-Free Dermal Matrix
US20100047308A1 (en) * 2006-09-26 2010-02-25 Jin Young Kim Production methods of virus inactivated and cell-free body implant
US20100185219A1 (en) * 2007-04-25 2010-07-22 Musculosketetal Transplant Foundation Reinforced biological mesh for surgical reinforcement

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5336616A (en) 1990-09-12 1994-08-09 Lifecell Corporation Method for processing and preserving collagen-based tissues for transplantation
US5613982A (en) 1994-03-14 1997-03-25 Cryolife, Inc. Method of preparing transplant tissue to reduce immunogenicity upon implantation
US5613892A (en) 1995-03-31 1997-03-25 Barton; Leslie W. Inflatable plush toy
US20030185702A1 (en) * 2002-02-01 2003-10-02 Wilson Burgess Methods for sterilizing tissue
US20050221484A1 (en) 2002-03-06 2005-10-06 University Of Cincinnati Apparatus for preparing a biocompatible matrix
US20040219133A1 (en) * 2003-03-21 2004-11-04 Lyles Mark B. Keratinocyte-fibrocyte concomitant grafting for wound healing
US20070269791A1 (en) 2003-12-25 2007-11-22 Yoshisiro Takami Method of Preparing Isolated Cell-Free Skin, Cell-Free Dermal Matrix, Method of Producing the Same and Composite Cultured Skin with The Use of the Cell-Free Dermal Matrix
US20060073592A1 (en) * 2004-10-06 2006-04-06 Wendell Sun Methods of storing tissue matrices
US20060275377A1 (en) * 2005-03-16 2006-12-07 Musculoskeletal Transplan Foundation Soft tissue processing
US20100047308A1 (en) * 2006-09-26 2010-02-25 Jin Young Kim Production methods of virus inactivated and cell-free body implant
US20100185219A1 (en) * 2007-04-25 2010-07-22 Musculosketetal Transplant Foundation Reinforced biological mesh for surgical reinforcement

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Anthony P. Sclafani et al., "Evaluation of Acelluar Dermal Grafta (AlloDerm) sheet for Soft Tissue Augmentation". Arch Facial Plastic Surg. Apr.-Jun. 2001, vol. 3, pp. 101-103.
C.D. Richters et al., "Development of a dermal matrix from glycerol preserved allogenic skin". Cell Tissue Banking, 2008, 9:309-315.
International Search Report of PCT/US2010/000003 dated Aug. 31, 2010.
Sok-Siam Gouk et al., "Alterations of human acellular tissue matrix by gamma irridation: Histology, biomedical property, stability, in vitro cell repopulation, an remodeling". J. of Biomedical Mat. Research Part B Applied Biomaterials. vol. 84B, Issue 1, May 11, 2007, 205-217.
Supplementary European Search Report of EP 10 80 8431 dated Jul. 3, 2012.

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10702260B2 (en) 2016-02-01 2020-07-07 Medos International Sàrl Soft tissue fixation repair methods using tissue augmentation scaffolds
US11357495B2 (en) 2016-02-01 2022-06-14 Medos International Sarl Tissue augmentation scaffolds for use with soft tissue fixation repair systems and methods
US11484401B2 (en) 2016-02-01 2022-11-01 Medos International Sarl Tissue augmentation scaffolds for use in soft tissue fixation repair
US11523812B2 (en) 2016-02-01 2022-12-13 Medos International Sarl Soft tissue fixation repair methods using tissue augmentation constructs
US11938017B2 (en) 2016-02-01 2024-03-26 Medos International Srl Tissue augmentation scaffolds for use in soft tissue fixation repair
US11937803B2 (en) 2016-02-01 2024-03-26 Medos International Sarl Soft tissue fixation repair methods using tissue augmentation constructs
USD856517S1 (en) 2016-06-03 2019-08-13 Musculoskeletal Transplant Foundation Asymmetric tissue graft
US10945831B2 (en) 2016-06-03 2021-03-16 Musculoskeletal Transplant Foundation Asymmetric tissue graft
USD895812S1 (en) 2018-09-07 2020-09-08 Musculoskeletal Transplant Foundation Soft tissue repair graft
US10813743B2 (en) 2018-09-07 2020-10-27 Musculoskeletal Transplant Foundation Soft tissue repair grafts and processes for preparing and using same
US11642216B2 (en) 2018-09-07 2023-05-09 Musculoskeletal Transplant Foundation Soft tissue repair grafts and processes for preparing and using same

Also Published As

Publication number Publication date
WO2011019361A1 (fr) 2011-02-17
EP2464221A4 (fr) 2012-08-01
US20130013068A1 (en) 2013-01-10
EP2464221A1 (fr) 2012-06-20
CA2771032A1 (fr) 2011-02-17

Similar Documents

Publication Publication Date Title
US9888999B2 (en) Acellular dermal allografts and method of preparation
US20230414670A1 (en) Placental tissue grafts and improved methods of preparing and using the same
US11382933B2 (en) Xenograft soft tissue implants and methods of making
JP4535324B2 (ja) 殺菌された異種移植片組織
Walker et al. Stabilization and sterilization of pericardial scaffolds by ultraviolet and low-energy electron irradiation
EP1582224B1 (fr) Procede de traitement de tissu biologique par irradiation par hyperfrequences
KR101139434B1 (ko) 돼지피부를 이용한 드레싱재의 제조방법
EP3188596B1 (fr) Derme humain, préparation et utilisation
EP2219733B1 (fr) Procédé de traitement de derme et son utilisation
Lee et al. The effects of sterilization methods on lyophilized cartilage grafts in an experimental model
Guhathakurta et al. Is gamma irradiation as a secondary sterilization procedure required for decellularized xenogenic tissue material?
Shah et al. A Histological and Biomechanical Analysis of Human Acellular Dermis (HAD) Created Using a Novel Processing and Preservation Technique
Kwak et al. Skin Graft Survival in Genetically Identical Bone Marrow Mesenchymal Stem Cells Cloned Pigs with Different Mitochondrial Haplotypes: 2524
Hussein et al. The Effects of Sterilization on the Biological Properties of Tissue-Engineered Porcine Liver: 2522
PL233525B1 (pl) Przeszczep oraz sposób przygotowania przeszczepu do regeneracji tkanek, zwłaszcza w obrębie jamy ustnej

Legal Events

Date Code Title Description
AS Assignment

Owner name: AZIYO BIOLOGICS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TISSUE BANKS INTERNATIONAL, INC.;REEL/FRAME:036959/0423

Effective date: 20151104

AS Assignment

Owner name: TISSUE BANKS INTERNATIONAL, MARYLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FORSELL, JAMES;FAN, FRANK;SIGNING DATES FROM 20120830 TO 20151030;REEL/FRAME:040206/0377

AS Assignment

Owner name: ALOSTAR BANK OF COMMERCE, GEORGIA

Free format text: SECURITY INTEREST;ASSIGNOR:AZIYO BIOLOGICS, INC.;REEL/FRAME:042100/0398

Effective date: 20170327

AS Assignment

Owner name: MIDCAP FINANCIAL TRUST, AS AGENT, MARYLAND

Free format text: SEURITY INTEREST (TERM);ASSIGNORS:AZIYO BIOLOGICS, INC.;AZIYO MED, LLC;REEL/FRAME:043413/0942

Effective date: 20170531

Owner name: MIDCAP FINANCIAL TRUST, AS AGENT, MARYLAND

Free format text: SECURITY INTEREST (REVOLVING);ASSIGNORS:AZIYO BIOLOGICS, INC.;AZIYO MED, LLC;REEL/FRAME:043414/0001

Effective date: 20170531

STCF Information on status: patent grant

Free format text: PATENTED CASE

AS Assignment

Owner name: MIDCAP FINANCIAL TRUST, AS AGENT, MARYLAND

Free format text: REAFFIRMATION & AMENDMENT TO SECURITY INTEREST (REVOLVING);ASSIGNORS:AZIYO BIOLOGICS, INC.;AZIYO MED, LLC;REEL/FRAME:049842/0107

Effective date: 20190715

Owner name: MIDCAP FINANCIAL TRUST, AS AGENT, MARYLAND

Free format text: REAFFIRMATION & AMENDMENT TO SECURITY INTEREST (TERM);ASSIGNORS:AZIYO BIOLOGICS, INC.;AZIYO MED, LLC;REEL/FRAME:049842/0132

Effective date: 20190715

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4

AS Assignment

Owner name: MIDCAP FINANCIAL TRUST, MARYLAND

Free format text: RELEASE BY SECURED PARTY;ASSIGNORS:AZIYO BIOLOGICS, INC.;AZIYO MED, LLC;REEL/FRAME:061161/0001

Effective date: 20220810

Owner name: MIDCAP FUNDING IV TRUST, MARYLAND

Free format text: RELEASE BY SECURED PARTY;ASSIGNORS:AZIYO BIOLOGICS, INC.;AZIYO MED, LLC;REEL/FRAME:061164/0532

Effective date: 20220810

Owner name: SWK FUNDING LLC, TEXAS

Free format text: SECURITY INTEREST;ASSIGNORS:AZIYO BIOLOGICS, INC.;AZIYO MED, LLC;REEL/FRAME:060792/0045

Effective date: 20220810

AS Assignment

Owner name: ELUTIA MED LLC, MARYLAND

Free format text: CHANGE OF NAME;ASSIGNOR:AZIYO MED, LLC;REEL/FRAME:064923/0704

Effective date: 20230906

Owner name: ELUTIA INC., MARYLAND

Free format text: CHANGE OF NAME;ASSIGNOR:AZIYO BIOLOGICS, INC.;REEL/FRAME:064923/0361

Effective date: 20230906